This page shows you your search results in order of date. This is page number 18.
Order by Relevance | Date
Total 12496 results found since Jan 2013.
Only 1 in 5 U.S. adults with opioid use disorder received medications to treat it in 2021
NIH and CDC study finds telehealth associated with increased likelihood of receiving evidence-based standard of care
Source: NIDA News - August 7, 2023 Category: Addiction Tags: Addiction Science, Adults, Advocates, Buprenorphine, Health Disparities, Methadone, Naltrexone, Opioids, Recovery, Treatment, Health and Medical Professionals, Media, Treatment, News Release Source Type: news
Out-of-Pocket Costs and Payer Types for Buprenorphine Among US Youth Aged 12 to 19 Years
This cross-sectional study examines out-of-pocket costs and payer types for buprenorphine prescriptions filled for youth aged 12 to 19 years at US retail pharmacies.
Source: JAMA Pediatrics - August 7, 2023 Category: Pediatrics Source Type: research
Out-of-Pocket Costs and Buprenorphine Discontinuation for Opioid Use Disorder
This cohort study examined the association between out-of-pocket costs for an initial buprenorphine prescription and its discontinuation among commercially insured US adults with opioid use disorder.
Source: JAMA Internal Medicine - August 7, 2023 Category: Internal Medicine Source Type: research
Unfilled prescriptions: Surveying patients' experiences with buprenorphine treatment in Massachusetts before and during the COVID-19 pandemic
CONCLUSIONS, AND SCIENTIFIC SIGNIFICANCE: This is the first investigation to report unfilled prescriptions during the pandemic and an association with opioid use. Unfilled prescriptions may contribute to relapse and partially explain increased overdose deaths during COVID-19.PMID:37543849 | DOI:10.1111/ajad.13460
Source: American Journal on Addictions - August 6, 2023 Category: Addiction Authors: Joseph A Rosansky Mark Albanese Joshua Phillips Zev Schuman-Olivier Source Type: research
Buprenorphine and methadone differentially alter early brain development in human cortical organoids
Neuropharmacology. 2023 Aug 3:109683. doi: 10.1016/j.neuropharm.2023.109683. Online ahead of print.ABSTRACTBuprenorphine (BUP) and methadone (MTD) are used for medication-assisted treatment (MAT) in opioid use disorder. Although both medications show improved maternal and neonatal outcomes compared with illicit opioid use during pregnancy, BUP has exhibited more favorable outcomes to newborns than MTD. The underlying cellular and molecular mechanisms for the difference between BUP and MTD are largely unknown. Here, we examined the growth and neuronal activity in human cortical organoids (hCOs) exposed to BUP or MTD. We fou...
Source: Neuropharmacology - August 5, 2023 Category: Drugs & Pharmacology Authors: Hang Yao Daisy Hu Juan Wang Wei Wu Helen H Zhao Lu Wang Joe Gleeson Gabriel G Haddad Source Type: research
Qualitative Analysis of Patient Perspectives of Buprenorphine After Transitioning from Long-Term, Full-Agonist Opioid Therapy Among Veterans with Chronic Pain.
Guidelines recommend consideration of modification, tapering, or discontinuation of long-term, full-agonist opioid therapy when harms outweigh benefits; one alternative to tapering or discontinuing full-agonist opioids for the management of chronic pain is switching to the partial agonist buprenorphine. As the use of buprenorphine for pain expands, understanding the patient experience during and after transition to buprenorphine is critical. We conducted 45- to 60-minute semi-structured qualitative interviews with 19 patients to understand the experiences of patients with chronic pain actively maintained on buprenorphine a...
Source: The Journal of Pain - August 5, 2023 Category: Materials Science Authors: Sara N. Edmond, Danielle M. Wesolowicz, Jennifer L. Snow, Sophia Currie, Amanda Jankelovits, Manik S. Chhabra, William C. Becker Source Type: research
Neonatal opioid toxicity: opioid withdrawal (abstinence) syndrome with emphasis on pharmacogenomics and respiratory depression
Arch Toxicol. 2023 Aug 3. doi: 10.1007/s00204-023-03563-8. Online ahead of print.ABSTRACTThe increasing use of opioids in pregnant women has led to an alarming rise in the number of cases of neonates with drug-induced withdrawal symptoms known as neonatal opioid withdrawal syndrome (NOWS). NOWS is a toxic heterogeneous condition with many neurologic, autonomic, and gastrointestinal symptoms including poor feeding, irritability, tachycardia, hypertension, respiratory defects, tremors, hyperthermia, and weight loss. Paradoxically, for the management of NOWS, low doses of morphine, methadone, or buprenorphine are administered...
Source: Archives of Toxicology - August 3, 2023 Category: Toxicology Authors: Brian A Baldo Source Type: research
